Sweden boosts life sciences
Enlarge image


Sweden boosts life sciences

21.09.2012 - The Swedish Government is set to boost its life sciences industry with a US$320m investment over the next four years.

Swedish Prime Minister Fredrik Reinfeldt confirmed the country’s largest ever investment into the life sciences. Speaking at SciLifeLab in Stockholm, a major research infrastructure project aimed at maintaining the country’s position in protein science, Reinfeldt announced a package of measures totalling US$1.7bn over the next four years, of which $ 320 million is devoted to life sciences. According to the decision of Reinfeldt and four ministers, the budget of SciLifeLab will be doubled to a total of US$100m. The centre combines state-of-the-art research infrastructure with a broad knowledge in translational medicine and molecular bioscience in order to translating discoveries into both tools and therapies. Additionally, US$220m will be pumped into drug discovery, clinical research, antibiotic resistance research, health in aging and the use of patient registries. 

Most of the money will be invested into the Stockholm-Uppsala biocluster which is home to more than 50% of Sweden’s thriving life science companies. Stockholm-Uppsala Life Sciences CEO Ola Bjorkman welcomed the Prime Minister’s commitment: “In our recently published report, we pointed out the ambitious, future plans for further strengthening the life science sector in Stockholm-Uppsala, thereby ensuring that the region remains a truly global life science cluster. In particular, the investment in SciLifeLab with its cutting edge research infrastructure combined with parallel investments in drug discovery, clinical research and the use of patient registries open new avenues for developing more personalised and outcome-orientated healthcare.” 

According to a report published this August, the Stockholm-Uppsala region is one of the largest clusters in Europe. According to official sources on limited public companies, the region is home to 633 companies, which employ 23,376 staff and had a combined turnover of €20bn in 2010. More than 16,000 employees (70%) work with R&D-orientated companies while 30% are distributors. Pharmaceutical companies such as AstraZeneca (5,600 jobs) employ 13,500 staff followed by medical technology firms 4,700, biotech tools & supply enterprises such as GE Healthcare (1,225 jobs) with 2,750 (12%), CROs and other services with 1,250 staff and diagnostics companies with 1,050 jobs.


09.10.2015 The US pricing controversy is reverberating halfway across the globe. Shield Therapeutics has taken its IPO plans off the table. Market conditions are too volatile, the company says.


07.10.2015 T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major facility that will house 200 staff.

Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


18.09.2015 AstraZeneca has partnered up with the US Department of Health in order to accelerate the development of new antibiotics. The goal: to be prepared for multi-resistant bugs – and for bioterrorism.


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • PHARMING (NL)0.31 EUR19.23%


  • THERAMETRICS (CH)0.04 CHF-33.33%
  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • THROMBOGENICS (B)4.13 EUR48.6%
  • OREXO (S)66.00 SEK36.9%
  • ZEALAND PHARMA (DK)156.00 DKK22.4%


  • THERAMETRICS (CH)0.04 CHF-33.3%
  • TIGENIX (B)0.88 EUR-27.9%


  • KARO BIO (S)43.60 SEK5282.7%
  • CHRONTECH PHARMA (S)0.35 SEK337.5%
  • GALAPAGOS (B)38.43 EUR225.7%


  • NEOVACS (F)0.70 EUR-77.8%
  • BIOTEST (D)19.15 EUR-74.6%
  • EVOCUTIS (UK)0.16 GBP-70.9%

No liability assumed, Date: 08.10.2015